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care community), but crucial, step of reaching out to previous investiga-
torswith large genotyped sepsis cohorts. This VPS13A ﬁnding replicated
to a reasonable extent (associatedwith SOFA severity of illness score) in
a second large cohort of patients from the PROGRESS study
(ClinicalTrials.gov: NCT02782013). Finally, taking all genetic variants
found by sequencing across the VPS13A gene, the VPS13A gene wasSepsis triggers multiple parallel inﬂammatory signaling pathways.
Of these pathways, which ones contributemost substantially to adverse
outcomes and, therefore, are relevant targets for new therapies? N100
clinical trials of mediator modulators in sepsis patients have failed
(Marshall, 2014) suggesting that we need new information to direct
our search. In other disease states a genome-wide association study de-
sign is an unbiased approach that has identiﬁed genes in key pathways
(Altshuler et al., 2008). For example, PCSK9was discovered using genet-
ic association analysis of patients who had LDL levels measured
(Abifadel et al., 2003). This has led to the introduction of PCSK9 inhibi-
tors as a treatment for hypercholesterolemia where other treatments
have failed. Can a similar genetic association strategy work in the com-
plex milieu of sepsis?
In the current issue of EBioMedicine, (2016-in this issue) conducted a
genome-wide association study for 28-day mortality, initially in 740
septic patients. The authors followed standard quality control practices
to limit any potential methodological errors in their discovery GWAS.
From 644,699 SNPs they imputed 7,993,459 SNPs for their GWAS
analysis.
These investigators found that a missense genetic variant located
within the VPS13A genewas associatedwith 28-daymortality in sepsis.
This was the strongest association observed within the primary GWAS
analysis (p = 8.2 × 10−8). The minor allele, associated with adverse
outcome, occurred only 1% of the time so this association is very suscep-
tible to a false positive result since only a small number of patients
would carry this adverse genetic variant – the conclusions are based
on a few “affected” patients. Therefore, replication of this ﬁnding was/j.ebiom.2016.08.043, http://
081 Burrard Street, Vancouver,
. This is an open access article underessential. These investigators took the relatively rare (within the critical
also found to be associated with 28-day mortality. A bioinformatics in
silico analysis suggests that this protein-altering SNP (rs117983287) is
predicted to be highly deleterious to VPS13A function. The original ﬁnd-
ing plus replication and further support from the sequencing study and
in silico analysis leads to the potentially important and exciting ﬁnding
that a signalingpathway involvingVPS13A is associatedwith sepsis out-
come. Not much is known about VPS13A function as it relates to sepsis
(Munoz-Braceras et al., 2015) so much work remains. Indeed, there are
many other genes in this region so it is not yet certain that VPS13A caus-
ally impacts sepsis outcome.
The authors identiﬁed 13 other genetic variants that are promising
candidates. None of these additional genetic variants reached the pre-
speciﬁed level of statistical signiﬁcance and therefore do not meet the
discovery threshold but remain as promising candidates requiring fur-
ther work and validation. When tested for replication in the collabora-
tors' genotyped sepsis cohorts, none replicated to the same extent as
VPS13A. Among this set, the best candidates included CRISPLD2 (p =
5.99 × 10−6) and a region on chromosome 13q21.33 (p= 3.34 × 10−7).
Reversing the replication strategy, these investigators tested for rep-
lication of top association ﬁndings previously reported by Rautanen et
al. (Rautanen et al., 2015). They did not observe directionally similar sig-
niﬁcant ﬁndings for any of the reported SNPs. Again, it must be appreci-
ated that for genetic association studies, the currently reported cohort is
quite small and therefore does not have much statistical power to ﬁnd
true associations.
The use of previous data to “look-up” potential new discoveries is a
very encouraging event. First, replication of the key result is impressive
validation and greatly increases the probability that the primary discov-
ery is biologically real and not a statistical ﬂuke. Second, sharing of data
is an exciting trend that will certainly improve the veracity of reported
results. Another encouraging step was the use of gene-based analysis
for replication. Single SNP associations may not identify causal SNPs
andmay simply bemarkers in linkage disequilibriumwith the underly-
ing causal genetic variants. Sequencing all SNPs within the identiﬁed
gene is a more powerful approach (Lee et al., 2012). The increasedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the smaller number of patients within this substudy in the current re-
port. Nevertheless, replication of gene association greatly reduces that
chance that a SNP association is a false positive result.
The current report highlights bad and good features of genetic asso-
ciation studies in sepsis, ARDS, and critical illness. A key bad feature is
the relatively low powerwe currently have tomake discoveries because
we have not put together sufﬁciently large genotyped sepsis cohorts.
Cohorts in the tens of thousands have successfully identiﬁed key
genes in, for example, atherosclerosis and asthma. This has led to the de-
velopment of highly successful new drugs. The very good feature of the
current report is that these investigators, and indeed the critical care
community, are now starting to coalesce in order to address the impor-
tant observations arising from genetic association studies. Let's put to-
gether the ﬁrst N10,000 patient genetic association study in sepsis and
start to make the really exciting discoveries that will transform patient
care and outcomes.
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